.jpeg)
Which country is Sotorasib produced in?
Sotorasib (Sotorasib) is an acrylamide-derived KRAS inhibitor developed by Amgen, also known as AMG-510, for the treatment of KRAS It is the first experimental KRAS inhibitor for locally advanced or metastatic non-small cell lung cancer (NSCLC) with G12C mutation. The mechanism of action of sotoraxib is by inhibiting the G12C mutation of the KRAS gene, which causes abnormal proliferation and growth of cancer cells. It binds to the mutated KRAS protein and blocks its activity, thereby interfering with the signaling pathways of cancer cells and reducing the proliferation ability of cancer cells.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
